ストックスクリーナーアプリを入手
35.71
1.60%
-0.58
前日終値:
$36.29
開ける：
$36.24
24時間の取引高:
900.84K
Relative Volume:
0.62
時価総額：
$2.83B
収益：
-
当期純損益:
$-119.67M
株価収益率:
-13.08
EPS:
-2.73
ネットキャッシュフロー:
$-97.30M
1週間 パフォーマンス:
-3.85%
1か月 パフォーマンス:
-8.79%
6か月 パフォーマンス:
+149.72%
1年 パフォーマンス:
+191.51%
1日の値動き範囲:
$35.66
$36.61
1週間の範囲:
$35.01
$37.60
52週間の値動き範囲:
$8.241
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
名前
Mineralys Therapeutics Inc
セクター
電話
(888) 378-6240
住所
150 N. RADNOR CHESTER ROAD, RADNOR
MLYS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
35.71 | 2.87B | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-11 | 開始されました | Jefferies | Hold |
| 2024-07-10 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-02 | 開始されました | Goldman | Buy |
| 2023-03-07 | 開始されました | BofA Securities | Buy |
| 2023-03-07 | 開始されました | Credit Suisse | Outperform |
| 2023-03-07 | 開始されました | Evercore ISI | Outperform |
| 2023-03-07 | 開始されました | Guggenheim | Buy |
| 2023-03-07 | 開始されました | Stifel | Buy |
| 2023-03-07 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Mineralys Therapeutics Inc (MLYS) 最新ニュース
Nasdaq Moves: Is Mineralys Therapeutics Inc stock a safe investment in uncertain marketsJuly 2025 Outlook & Real-Time Volume Spike Alerts - moha.gov.vn
Behavioral Patterns of MLYS and Institutional Flows - Stock Traders Daily
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Mineralys Therapeutics (MLYS) stock slides today as biotech weakens; FDA filing timeline in focus - ts2.tech
Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Down 3.4%What's Next? - MarketBeat
Oversold Conditions For Mineralys Therapeutics (MLYS) - Nasdaq
Simplify Asset Management Inc. Takes Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Commit To Buy Mineralys Therapeutics At $22.50, Earn 16.1% Annualized Using Options - Nasdaq
Mineralys Therapeutics prices $175M stock offering - MSN
Mineralys: Pre-NDA Feedback Sets Stage For A Pivotal 2026 (NASDAQ:MLYS) - Seeking Alpha
Swedbank AB Sells 84,500 Shares of Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics Earnings Notes - Trefis
Voya Investment Management LLC Grows Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar - sharewise.com
Is It Too Late To Consider Mineralys Therapeutics After Its Huge 2025 Share Price Surge - Yahoo Finance
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow - Finviz
Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears - Yahoo Finance
If These Biotech Stocks Pull Back, I'll Be Ready to Pull the Trigger - TheStreet Pro
Mineralys Therapeutics Shares Climb on Strong Results from Kidney Disease Trial - MSN
(MLYS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Will Mineralys Therapeutics Inc. stock maintain dividend yieldTrade Entry Report & AI Enhanced Execution Alerts - Улправда
Did JAMA’s “Research of the Year” Spotlight on Lorundrostat Just Shift Mineralys Therapeutics’ (MLYS) Investment Narrative? - Sahm
Analyst Upgrade: Can Mineralys Therapeutics Inc stock attract ESG capital inflowsEarnings Growth Summary & Weekly Stock Performance Updates - moha.gov.vn
Bank of America Securities Sticks to Their Buy Rating for Mineralys Therapeutics, Inc. (MLYS) - The Globe and Mail
Is Mineralys Therapeutics Inc. stock near bottom after decline2025 Technical Patterns & Fast Exit and Entry Strategy Plans - Улправда
Mineralys stock price target raised to $52 by Stifel on strong trial data By Investing.com - Investing.com Nigeria
Stifel Maintains Mineralys Therapeutics (MLYS) Buy Recommendation - Nasdaq
Why Mineralys Therapeutics Inc. stock is in analyst buy zone2025 Fundamental Recap & Fast Entry High Yield Stock Tips - Улправда
Mineralys stock price target raised to $52 by Stifel on strong trial data - Investing.com South Africa
Can Mineralys Therapeutics Inc. stock deliver strong Q4 earningsJuly 2025 Momentum & Advanced Swing Trade Entry Plans - DonanımHaber
Is Mineralys Therapeutics Inc. stock ready for breakoutIPO Watch & Weekly Return Optimization Alerts - Улправда
Can Mineralys Therapeutics Inc. stock attract ESG capital inflowsWeekly Gains Summary & High Yield Equity Trading Tips - DonanımHaber
Is Mineralys Therapeutics Inc. stock a safe investment in uncertain marketsQuarterly Profit Summary & Daily Technical Stock Forecast Reports - DonanımHaber
JAMA Spotlights Mineralys Trial as Breakthrough for Resistant Hypertension - MyChesCo
Wall Street analysts think Mineralys Therapeutics, Inc. (MLYS) could surge 27.55%: Read this before placing a bet - MSN
Mineralys Therapeutics (MLYS): Reassessing Valuation After JAMA Spotlight on Lorundrostat’s Phase 3 Launch-HTN Trial - Sahm
Is Mineralys Therapeutics Inc a good long term investmentFinancial Sector Performance & Budget Friendly Trading Alerts - earlytimes.in
Did JAMA’s “Research of the Year” Nod for Launch-HTN Just Shift Mineralys Therapeutics’ (MLYS) Investment Narrative? - Sahm
Boothbay Fund Management LLC Sells 116,877 Shares of Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Aug Opening: Is Mineralys Therapeutics Inc stock a contrarian buyPortfolio Performance Report & Daily Technical Stock Forecast Reports - moha.gov.vn
Biotech Shake-Up: New CEO Takes Helm at Jubilant Therapeutics - MyChesCo
Mineralys hypertension drug trial featured in JAMA’s top research of 2025 - Investing.com Canada
Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) 'Research of the Year” Roundup - The Manila Times
Mineralys Therapeutics' Launch-HTN Trial Recognized by JAMA as One of 2025's Most Impactful Studies - Quiver Quantitative
Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup - GlobeNewswire
Mineralys Therapeutics’ Earnings Call Highlights Positive Outlook - MSN
73,921 Shares in Mineralys Therapeutics, Inc. $MLYS Acquired by Walleye Capital LLC - MarketBeat
HighVista Strategies LLC Takes Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Price-Driven Insight from (MLYS) for Rule-Based Strategy - news.stocktradersdaily.com
Swiss National Bank Invests $838,000 in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
22NW LP Purchases 98,698 Shares of Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics Inc (MLYS) 財務データ
収益
当期純利益
現金流量
EPS
Mineralys Therapeutics Inc (MLYS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Congleton Jon | Chief Executive Officer |
Nov 21 '25 |
Option Exercise |
0.54 |
24,082 |
13,004 |
655,387 |
| Slingsby Brian Taylor | Director |
Nov 20 '25 |
Sale |
43.35 |
1,000,000 |
43,350,000 |
7,903,838 |
0.57%
大文字化:
|
ボリューム (24 時間):